March 27, 2023
RegMed Investors’ (RMi) closing bell: a BUY zone or just another algorithm rebound?
March 24, 2023
RegMed Investors’ (RMi) closing bell: the cell and gene therapy sector reversed losses to close positive
March 23, 2023
RegMed Investors’ (RMi) closing bell: momentum interrupts sector’s share pricing bouncing luckily to the upside
March 22, 2023
RegMed Investors’ (RMi) closing bell: more push and pull-down share pricings
March 21, 2023
RegMed Investors’ (RMi) closing bell: an upside after negative actions
March 20, 2023
RegMed Investors’ (RMi) closing bell: cell and gene therapy equities are back in the trenches with share pricing hunkering down
March 17, 2023
RegMed Investors’ (RMi) closing bell: a second Black Swan event this week
March 16, 2023
RegMed Investors’ (RMi) closing bell: sector responds to being oversold reversing some declines
March 15, 2023
RegMed Investors’ (RMi) closing bell: cell and gene therapy sector suffers from Autophobia
March 13, 2023
RegMed Investors’ (RMi) closing bell: sector equities turn up from being oversold clouded by SVB’s decline
March 10, 2023
RegMed Investors’ (RMi) closing bell: bad goes to worse and fear for cell and gene therapy sector cash positions
March 9, 2023
RegMed Investors’ (RMi) closing bell: the sector does the limbo dance and low it went?
March 8, 2023
RegMed Investors’ (RMi) closing bell: the cell/gene therapy sector opened down, climbed up and then fell back
March 7, 2023
RegMed Investors’ (RMi) closing bell: indexes sell-off after Jerome spoke
March 6, 2023
RegMed Investors’ (RMi) closing bell: sector share pricing evaporated as upcoming Fed policy stymies share pricing
March 3, 2023
RegMed Investors’ (RMi) closing bell: sector gets a push pull
March 2, 2023
RegMed Investors’ (RMi) closing bell: the cell and gene therapy sector’s feeling the lack of sentiment
March 1, 2023
RegMed Investors’ (RMi) closing bell: the cell/gene therapy sector slumps after mid-day
February 28, 2023
RegMed Investors’ (RMi) closing bell: a volatile February comes to an end as Q4 and FY22 keep rolling out
February 27, 2023
RegMed Investors’ (RMi) closing bell: hunker down but, be aware of earnings backlash
February 22, 2023
RegMed Investors’ (RMi) closing bell: the sector’s continuous menace - sustainability
February 21, 2023
RegMed Investors’ (RMi) closing bell: extending losses as fear defines the cell/gene therapy sector with Q4 and FY22 earnings release bringing more pressures
February 17, 2023
RegMed Investors’ (RMi) closing bell: a concluding weekly reverse as the oversold sector was recognized closing positive after a bad morning
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors